As such, the stage at diagnosis may also be higher than for HER2-negative tumors, which can impact survival. Research has shown that HER2-positive early breast cancers (stage I and stage II ...

"For patients receiving neoadjuvant therapy for hormone receptor‒positive, HER2-negative breast cancer, right now the standard is chemotherapy, but there are efforts looking at what other ...

Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Overall survival data from the CAPItello-291 trial is still immature ... These data reinforced the use of capivasertib in combination with fulvestrant for the treatment of HR-positive HER2-negative ...

Phase 2 trial results support further development of camizestrant for the treatment of estrogen receptor-positive, HER2-negative breast cancer, according to researchers.

Although CDK4/6 inhibitors such as Ibrance are well-established treatments for HR-positive, HER2-negative breast cancer ... median progression-free survival time by 15.2 months to 44.3 months.